Regeneron’s R&D (29% of revenue) creates treatments for Diabetic Retinopathy & Atopic Dermatitis
Register to read the full analysis —or— Upgrade to access more features
#development
#research
#Drug
#ebola
Actual Direct Impact
Share this Analysis
Keen to rectify an issue with this analysis?
Report issue
There is no comment yet.